Data from, in total, 45 adults with T1D [30 females (67%)] were included in this study. Baseline characteristics of the included cohort are displayed in Table 1 . Information regarding comorbidities as well as baseline characteristics when participants were split into groups based on HbA1c, and cardiorespiratory fitness (CRF) can be found in supplementary file; Tables S1 , S2 and S5 , respectively.
Participants were using a range of different insulin pumps: Medtronic [(Northridge, CA, USA) n = 28; MiniMed 640G (n = 14), MiniMed 670G (n = 1), MiniMed 780G (n = 10), Paradigm Veo (n = 3)]; Insulet [(Bedford, MA, USA) n = 9 Omnipod DASH]; Tandem Diabetes [(San Diego, CA, USA) n = 5 t:slim X2]; YPSOMED [(Burgdorf, Switzerland) n = 1 YpsoPump]; and Roche Diabetes Care [(Mannheim, Germany) n = 2 Accu‐Chek Insight]. Of the 45 participants, 39 (87%) were using insulin Aspart with the remaining six using Fast‐acting insulin Aspart (NovoNordisk, Bagsværd, Denmark).
Participants were using a range of different insulin pumps: Medtronic [(Northridge, CA, USA) n = 28; MiniMed 640G (n = 14), MiniMed 670G (n = 1), MiniMed 780G (n = 10), Paradigm Veo (n = 3)]; Insulet [(Bedford, MA, USA) n = 9 Omnipod DASH]; Tandem Diabetes [(San Diego, CA, USA) n = 5 t:slim X2]; YPSOMED [(Burgdorf, Switzerland) n = 1 YpsoPump]; and Roche Diabetes Care [(Mannheim, Germany) n = 2 Accu‐Chek Insight]. Of the 45 participants, 39 (87%) were using insulin Aspart with the remaining six using Fast‐acting insulin Aspart (NovoNordisk, Bagsværd, Denmark).